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Systemic amyloidosis is a usually fatal disease causedby extra-
cellular accumulation of abnormal protein fibers, amyloid
fibrils, derived by misfolding and aggregation of soluble globu-
lar plasma protein precursors. BothWT and genetic variants of
the normal plasma protein transthyretin (TTR) form amyloid,
but neither themisfolding leading to fibrillogenesis nor the ana-
tomical localization of TTR amyloid deposition are understood.
We have previously shown that, under physiological conditions,
trypsin cleaves human TTR in a mechano-enzymatic mecha-
nism that generates abundant amyloid fibrils in vitro. In sharp
contrast, the widely used in vitro model of denaturation and
aggregation of TTR by prolonged exposure to pH 4.0 yields
almost no clearly defined amyloid fibrils.However, the exclusive
duodenal location of trypsin means that this enzyme cannot
contribute to systemic extracellular TTR amyloid deposition in
vivo. Here, we therefore conducted a bioinformatics search for
systemically active tryptic proteases with appropriate tissue dis-
tribution, which unexpectedly identified plasmin as the leading
candidate. We confirmed that plasmin, just as trypsin, selec-
tively cleaves human TTR between residues 48 and 49 under
physiological conditions in vitro. Truncated and full-length
protomers are then released from the native homotetramer and
rapidly aggregate into abundant fibrils indistinguishable from
ex vivo TTR amyloid. Our findings suggest that physiological
fibrinolysis is likely to play a critical role in TTR amyloid for-
mation in vivo. Identification of this surprising intersection
between two hitherto unrelated pathways opens new avenues
for elucidating themechanisms of TTR amyloidosis, for seeking
susceptibility risk factors, and for therapeutic innovation.
The in vivo processes responsible for misfolding of native
precursors, for formation of amyloid fibrils, and for the ana-
tomical localization of amyloid deposition are not known either
for transthyretin (TTR)4 or for other types of systemic amyloi-
dosis (1). The late onset of TTR amyloidosis, despite the abun-
dance of circulating TTR from birth, is also mysterious.
In vitro studies suggest that TTR fibrillogenesis requires dis-
sociation of the native tetramer, which is favored by the desta-
bilizing mutations that are known to be amyloidogenic. Indeed
the most aggressive, earlier onset forms of the disease are
caused by highly destabilizing mutations whereas mutations
that increase tetramer stability prevent amyloidosis (2). A sin-
gle, selective, proteolytic cleavage in the loop interconnecting
strands C andDdramatically destabilizes the native tetramer in
themost unstable amyloidogenic S52PTTR (3) and the unusual
Glu-51_Ser-52 duplicate variant (4) leading to abundant amy-
loid formation. In addition, mechanical forces, generated by a
combination of physiological fluid flow and contactwith hydro-
phobic surfaces, enhance susceptibility to this cleavage and
thus uniquely promote formation of unequivocal amyloid
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fibrils, both by other amyloidogenic variants that are more sta-
ble than S52P and by WT TTR (5).
Trypsin, which we have previously used to trigger TTR amy-
loid fibril formation in vitro, is synthesized only by the exocrine
pancreas and secreted exclusively into the small bowel lumen. It
is therefore unlikely to be involved in pathogenesis of systemic
TTR amyloidosis. However, we show here that plasmin, identi-
fied in our comprehensive bioinformatics search for patho-
physiologically plausible candidate proteases, effectively repli-
cates the role of trypsin in in vitro TTR amyloidogenesis.
Furthermore, the normal, ubiquitous, continuous, physiologi-
cal activation of plasminogen is fully consistent with a key role
of plasmin in TTR amyloidogenesis.
Results
Search for candidate tryptic proteases in theMEROPS
database
There were 344 peptidases in theMEROPS database (6) able
to cleave substrateswith tryptic specificity, that is C-terminal to
lysine (position P1), and with relevantly wider tissue distribu-
tion than trypsin itself. Seventy-five of them were both human
and extracellular according to the curated UniProt protein
database, themajority being either serine chymotrypsin–like or
metallopeptidase types (Table 1). Among the four enzymes
with specificity higher than 30% for lysine at P1 (Table 2), tryp-
sin was excluded because of its exocrine location. Tryptase
alpha did not trigger TTR amyloid formation in our fibrillogen-
esis assay (3) and kallikrein-related peptidase 12 had very mod-
est activity (Fig. S1). In contrast, plasmin not only fulfilled our
search criteria but its active site is also strikingly similar to that
of trypsin (Fig. 1).
Amyloidogenic cleavage of TTR by plasmin
Consistent with its known structure and proteolytic specific-
ity, plasmin did indeed trigger TTR amyloid formation in vitro,
although it was slightly less active than trypsin (Fig. 2). With
S52P TTR in solution, stirred at physiological pH and ionic
strength, and the same enzyme:TTRw/w ratio, the thioflavin T
(ThT) signal increased more rapidly in the presence of trypsin
than plasmin and reached a higher final value (Fig. 2A). Never-
theless, both samples contained abundant amyloid fibrils with
the pathognomonic amyloid red-green birefringence after
Congo Red staining when viewed in strong cross-polarized
light, and showing typical fibrillar morphology in negative
staining EM (Fig. 2, B and C). The crucial residue 49–127 frag-
ment produced by the specific amyloidogenic cleavage was
present after fibrillogenesis induced by plasmin but was slightly
less abundant than with trypsin (Fig. 2, D and E), consistent
with the longer lag phase and lower yield of fibrils (Fig. 2A).
However, as in our previous studies with trypsin, TTR amyloid
fibrillogenesis mediated by plasmin in the mechano-enzymatic
process was accelerated by seeding with preformed TTR amy-
loid fibrils, which eliminated the lag phase and produced a
Figure1. Structural and functional similaritiesbetween trypsinandplas-
min in complex with the peptide P3-P3 corresponding to sequence
46–51ofTTR.Thebackbonesof trypsin (magenta; PDB ID:3D65) andplasmin
(green; PDB ID: 3UIR) are overlaid; the catalytic triad, in ball and stick, with the
Asp residue, in sticks, that lead to the correct orientation of the Lys-substrate
(Lys-48 in TTR) are specifically highlighted. The numbering refers to trypsin
residues. The P3-P3 peptide backbone of textilinin-1 in the complex with
plasmin is shown in cyan. The side chain of Lys in position P1 is also repre-
sented in stickswith thedistances fromAsp-189. For clarity the corresponding
peptide complexed to trypsin is not shown.
Table 1
Bioinformatics search for trypsin like protease(s)
Summary of the human extracellular proteases identified in the MEROPS database
with lysine in position P1 of the substrate.
Clan Family Type Number
A A01 Asp_pepsin_like 3
C C01 Cys_papain_like 1
MA M01 Aminopeptidase_like 2
MA M10 Metallopeptidase 14
MA M12 Astacin_like 7
MA–MC M13–M43 Neprilysin_like; carboxypeptidase 7
PA S01 Ser_chymotrypsin_like 38
SB S08 Ser_subtilisin_like 2
SR S60 Ser_lactoferrin 1
Total 75
Table 2
Secreted peptidases with specificity for lysine in position P1 higher than 30%
Plasmin and tryptase have structural similarities with trypsin; the structure of kallikrein-related peptidase 12 is not known.
Enzymes
Specificity for
Lys at P1 Primary localization
(%)
S01.151: trypsin 1 60 Intestinal tract
S01.143: tryptase alpha 56 Lung, stomach, spleen, heart, and skin
S01.020: kallikrein-related peptidase 12 55 Salivary glands, stomach, uterus, trachea, prostate, thymus,
lung, colon, brain, breast, and thyroid
S01.233: plasmin 45 Plasma and many other extracellular fluids
Plasmin primes TTR amyloidogenesis
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higher final yield (Fig. S2). Plasmin-induced fibrillogenesis
was inhibited by 2-antiplasmin, the natural inhibitor of the
enzyme (Fig. 2F).
The critical importance of protease specificity for TTR amy-
loid formation was exemplified by the failure of three different,
potent, proteolytic enzymes, thrombin, chymotrypsin, and pro-
teinaseK, to trigger any amyloidogenesis (Fig. 2A).On the other
hand, all the amyloidogenicTTRvariants tested so far, aswell as
WT TTR, were cleaved by plasmin in our in vitro mechano-
enzymatic system. They all formed unequivocal amyloid fibrils,
although the yields were lower with V30M, L55P, and V122I
TTR than with S52P and were lowest with WT TTR (Fig. 3).
Crucially, the known, superstable, T119MTTR variant was not
cleaved at all (Fig. 3). These observations are fully consistent
with the usually earlier onset and more aggressive phenotypes
in carriers of amyloidogenic TTR mutations, compared with
the late onset ofWTTTR amyloidosis, and with the protection
against TTR amyloidosis in carriers of amyloidogenic TTR
gene mutations afforded by co-inheritance of the gene for the
T119M variant.
In contrast to the susceptibility of native TTR to cleavage by
plasmin, which was greatly enhanced by mechanical forces,
preformed TTR amyloid fibrils were completely resistant to
degradation by plasmin (Fig. S3). This differs fromA-amyloid
fibrils that are digested by plasmin, which has been suggested to
be a putative protective mechanism against amyloid formation
in Alzheimer’s disease (7).
From fibrin to fibril formation
To study the amyloidogenicity of plasmin in a more physio-
logical environment, we created a model fibrin clot on which
fibrinolysis was initiated in the presence of either the highly
amyloidogenic unstable S52P TTR variant or the superstable
nonamyloidogenic T119Mvariant. Polymerization and depoly-
merization were monitored by nonspecific light scattering at
350 nm (Fig. 4A) and by the specific spectrofluorimetric signal
of ThT binding to amyloid fibrils (Fig. 4B).
In phase I, fibrinogenwas converted into fibrin by addition of
thrombin, monitored by the rapid increase in turbidity. Once
the clot was formed, tissue plasminogen activator (tPA), plas-
Figure 2. Plasmin-mediated amyloid fibrillogenesis of S52P TTR. A, increase in ThT emission fluorescence for S52P TTR incubated in the presence of plasmin
comparedwithtrypsin.Noamyloid-specificThTsignalwasseenafter incubationofS52PTTRwiththrombin,chymotrypsin,orproteinaseK.BandC, negativelystained
transmissionelectronmicrographsofS52PTTRamyloid fibrils formed in thepresenceof trypsin (B) orplasmin (C).Scalebar, 100nm.D, 15%SDS-PAGEunder reducing
conditions.M, marker proteins (14.4, 20.1, 30.0, 45.0, 66.0, and 97.0 kDa); lane 1, S52P TTR at time 0; lane 2, S52P TTR fibrils formed in the presence of trypsin; and lane
3, S52P TTR fibrils formed in the presence of plasmin. E, immunoblot analysis of samples separated in 15% SDS-PAGE (see lanes 1, 2, and 3 in D). Position of marker
proteinsat15and10kDaare indicated.F, inhibitionby2-antiplasminof fibril formationbyS52PTTRmediatedby20ng/l plasmin. Thedatawerenormalized to the
ThT signal plateau in the sampleswithout2-antiplasmin.Mean S.D. of three replicates is shown. a.u., arbitrary units.
Plasmin primes TTR amyloidogenesis
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minogen, and TTR were gently layered on the clot surface, at
the time point shown (arrow) in Fig. 4, A and B, producing
physiological fibrinolysis of the clot as indicated by the rapid
decline in turbidity in phase II. When S52P TTR was present,
the initial fall in light scattering was swiftly followed by a sharp
rise that correlated with the appearance and increase in the
ThT amyloid fibril signal (Fig. 4B). In the presence of T119M
TTR, which is not susceptible to cleavage by plasmin and does
not form amyloid fibrils (5) (Fig. 3), there was no secondary rise
in turbidity and no ThT signal (Fig. 4, A–C).
Atomic force microscopy analysis of the reactants at the end
of the experiment with the stable T119M or the pathogenic
S52P variant TTR (that is 4 and 5 in Fig. 4, A–C) showed
remarkably different structures, consistent with the spectrom-
etry results. S52P TTR produced morphologically typical
mature amyloid fibrils, 4–7 nm in height (Fig. 4D) emerging
from a thick layer of short fibrils. No fibrillar material was seen
either with T119MTTR (Fig. 4E) or in the absence of any added
TTR (Fig. 4F). Only single globular structures and short beaded
chains were observed.
Discussion
The spectrum of systemic TTR amyloidosis comprises the
many very rare hereditary forms caused by different mutations
(8), the cardiac amyloidosis caused by the V122I variant in indi-
viduals of African origin (9) and cardiac amyloidosis, mostly in
elderlymen, caused byWTTTR (10). Recent advances in imag-
ing have shown that the latter is substantially more prevalent
than previously recognized (11). There are no licensed treat-
ments that arrest disease progression and TTR amyloidosis is
thus an important unmet medical need. Current trials of TTR
gene expression knockdown by experimental siRNA (12) and
antisense oligonucleotide (ASO) drugs (13) have shown prom-
ising results. However, elucidation of the mechanism underly-
ing the in vivo transition of native, soluble, globular, tetrameric
TTR into insoluble, polymeric, amyloid fibrils is crucial for
understanding the natural history of the disease and for design
of other effective therapies.
The influential original model of TTR denaturation and
aggregation at low pH (14) demonstrated that tetramer disas-
sembly is crucial, and that analogues of thyroxine, the natural
ligand of TTR, can inhibit this process (15). The observations
led to design, development, and clinical testing of tafamidis (16)
and diflunisal (17), compounds that stabilize TTR against acid
denaturation, for use as inhibitors of TTR amyloidogenesis,
mimicking the trans-suppressive effect of the TTR-stabilizing
T119Mvariant (2). Despite the capacity of tafamidis to increase
the stability of TTR in plasma through the occupancy of just
one of the two binding sites (18), its clinical use does not halt
disease progression in a substantial proportion of patients (19).
The limited clinical efficacy probably reflects the fact that the
low pHmodel does not represent the actual pathophysiological
mechanism of TTR amyloid fibrillogenesis. Indeed there is no
relevant in vivo location in which TTR could be exposed to the
acid conditions used in vitro.
We have recently demonstrated that specific proteolytic
cleavage of the residue 48–49 bond in the flexible loop con-
necting strands C and D, in just a single TTR protomer within
the native tetrameric TTR assembly, causes rapid dissociation
into cleaved and uncleaved protomers. Under physiological
conditions in vitro, these then swiftly form abundant TTR
fibrils, which are indistinguishable from ex vivo TTR amyloid
fibrils (3, 5). The whole process occurs in the presence of phys-
iological scale mechanical forces provided by stirring and by
exposure to hydrophobic surfaces. Discovery of the critical role
of proteolysis explains the almost universal presence of the
TTR residue 49–127 fragment in ex vivo TTR amyloid fibrils
(20). Other features consistent with the mechano-enzymatic
mechanism operating in vivo include the presence of a lag-
phase preceding fibrillogenesis, and acceleration of fibril for-
mation when preformed fibril seeds are present. We have also
shown that binding of small ligands by the intact TTR tetramer
significantly reduces its susceptibility to cleavage and aggrega-
tion. However, maximum inhibition is only achieved by ligands
that simultaneously occupy both the two binding sites and the
central channel between them in the core of the TTRmolecule
(21).
A crucial question about the mechano-enzymatic mecha-
nism has hitherto been the identity of the tryptic protease
responsible for TTR amyloidosis in vivo. The present demon-
stration of the efficacy of plasmin in vitro highlights it as
an extremely plausible candidate. Other potent proteolytic
enzymes were completely inactive in triggering TTR amyloid
formation in vitro. Kallikrein-related peptidase 12, which has
only very transient activity in vivo, did produce a small ThT
signal of amyloid formation with S52P TTR, the most unstable
and amyloidogenic TTR variant, but there was a long lag
phase and very modest yield. Plasmin mediates the essential
specific cleavage in TTR much more potently and, with clas-
sical kinetic phases of nucleation and elongation, it generates
abundant fibrils that are identical to ex vivo TTR amyloid
fibrils. The relative lower activity of plasmin compared with
trypsin cannot be easily explained. The remarkable self-di-
gestion of plasmin, once activated, may reduce its activity
and therefore delay the formation of the first fibrillar nuclei
thus contributing to a reduced yield of fibrils. A complete
Figure 3. Plasmin-mediated fibrillogenesis. Relative ThT emission fluores-
cence intensities of TTR samples at 1 mg/ml after 25 h incubation with shak-
ing in the presence of plasmin at an enzyme:substrate ratio of 1:50. Mean
S.D. of three replicates is shown.
Plasmin primes TTR amyloidogenesis
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characterization of the kinetics of all processes together with
the determination of the TTR–plasmin structure should
clarify the differences that we have observed. The several
amyloidogenic TTR variants tested so far and the WT
protein are all cleaved by plasmin, with varying efficiency
replicating the findings with trypsin, whereas the stable,
nonpathogenic, protective T119M variant is resistant. Fur-
thermore, plasmin is ubiquitously and continuously acti-
vated in vivo to provide for essential fibrinolysis on the vas-
cular wall and also in the extracellular matrix, precisely
where TTR amyloid is deposited.
The possible in vivo scenario of plasmin-mediated TTR
fibrillogenesis is summarized in Fig. 5. Plasminogen can be acti-
vated by tPAwithin the clot and also by urokinase plasminogen
activator (uPA) in the extracellular matrix. Sufficient proteoly-
sis of theTTR tetramer by plasminmay thenprovide the critical
concentration of both truncated and full-length TTR protom-
ers required for nucleation of fibrils. Once nucleation has
occurred, the elongation of fibrils can progress at lower concen-
trations of monomers provided by either of the plasminogen
activating pathways. Plasmin activity is finely regulated by
activators, including tPA and uPA, and inhibitors, including
2-plasmin inhibitor and plasminogen activator inhibitor. The
conditions for critical TTR cleavage, sufficient to initiate amy-
loidogenesis, may thus only arise rarely but there is certainly
scope for variation in this complex system. For example, phys-
iological fibrinolysis is notably affected by the intensity of nor-
mal physical activity (22). All these features of plasmin, com-
bined with the importance of mechanical forces, are consistent
with the prevalence of TTR amyloid deposition in the heart and
carpal tunnel, both of which are notable sites of continuous
repetitive vigorous movement. The pathogenetic significance
of plasmin also opens a broad and completely novel perspective
for investigation of factors that may determine individual
susceptibility and the natural history of the familial and
acquired forms of TTR amyloidosis, including the initiation,
progression, and tissue distribution of amyloid deposition.
In addition, the wholly unexpected and surprising conflu-
ence of the fibrinolysis pathway, the physiological remodel-
ing of the extracellular matrix regulated by urokinase (23),
and the pathogenesis of TTR amyloidosis are of considerable
fundamental interest.
Figure 4. From fibrin to fibrils. A and B, spectrophotometric absorbance/light scattering at 350 nm (A) and amyloid-specific ThT emission fluorescence (B)
during clotting of fibrinogen to fibrin (phase I) followed by fibrinolysis in the presence of S52P TTR (red) or of the highly stable T119M TTR variant (blue) (phase
II). Following fibrinolysis, increase in turbidity and ThTwere observed in the presence of S52P TTRwhereas neither of these signals increasedwhen T119M TTR
was present instead.Arrows indicate addition of tPA, plasminogen, and TTR. The results shown are themean S.D. of three independent experiments.C, wells
containing a solution of fibrinogen in the presence of 1) thrombin and 2) fibrin clot; 3) a solution of tPA, plasminogen, and TTR layered over the clot surface; 4)
fibrinolysis with no further aggregation in the presence of T119M TTR; 5) fibrinolysis in the presence of S52P TTR showing the turbidity of amyloid fibril
formation. D–F, surface plots of topographic tapping mode AFM images showing (D) the presence of fibrillar structures in the sample containing clot, tPA,
plasminogen, and S52P TTR; (E and F) the presence of globular structures in samples containing clot, tPA, and plasminogen (E) in the presence of T119M TTR
or (F) in the absence of any TTR isoform.
Plasmin primes TTR amyloidogenesis
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Experimental procedures
Reagents
Recombinant TTR variants were expressed and purified as
described previously (21). Human fibrinogen was isolated from
citrate-heparin–treated human plasma by affinity chroma-
tography on recombinant clamping factor 221–559 frag-
ment (24) and was absorbed with lysine-Sepharose 4B and
gelatin-Sepharose 4B to remove traces of plasminogen and
fibronectin, respectively. Enzymes purchased from Sigma-
Aldrich were plasmin (P1867), proteinase K (P2308), chymo-
trypsin (C2160000), tPA (T0831), plasminogen (SRP6518),
thrombin (T7572), and tryptase (T7063). Trypsin was pur-
chased from Promega (V5280) and recombinant human kal-
likrein 12 from Biotechne (3095-S.E.). All the enzymes used
were able to cleave the C-terminal end of Lys in the D-Val-
Leu-Lys 4-nitroanilide dihydrochloride peptide (Sigma-Al-
drich, V0882) following the manufacturer’s instructions. All
other reagents including 2-antiplasmin (SRP6313) were
purchased from Sigma-Aldrich unless otherwise stated.
MEROPS database search
MEROPS (https://www.ebi.ac.uk/merops/) is a manually
annotated database with information on more than 4000 pep-
tidases classified according to families and clans. The residues
of the proteolytic substrate are designated Pn—P4-P3-P2-P1--
P1-P2-P3-P4—Pm with  indicating the scissile bond.
Substrate specificity was based on the frequency of Lys at
position P1.
Proteolysis and fibrillogenesis of S52P TTR
Recombinant S52P TTR, 100 l volumes at 0.5 mg/ml in 20
mM Tris-HCl containing 150 mM NaCl, 5 mM CaCl2, pH 7.4,
containing 10 M ThT (25) was incubated at 37 °C in Costar
96-well black plates in the presence of a protease at an enzyme:
substrate ratio of 1:50. Plasmin, trypsin, thrombin, proteinase
K, chymotrypsin, tryptase alpha, and kallikrein 12 were tested.
The platewas sealedwith clear sealing film and subjected to 900
rpmdouble-orbital shaking. Bottom fluorescencewas recorded
at 500-s intervals (BMG LABTECH, FLUOstar Omega).
Homogenous 15% SDS-PAGE (GEHealthcare) under reducing
Figure 5. From fibrin to fibrils. Shown is a cartoon of the putative flow of events leading to TTR amyloid fibril formation caused by plasmin cleavage within the
physiological scenarioof fibrin formationandplasminogenactivation.CirculatingTTRcandiffuse toward theextracellular compartment (bluearrow), beentrapped in
the fibrin clot (greenarrow), or escape from it (grayarrow). In thepresenceof activatedplasminogenboth in thepresenceofuPA (extracellular compartment) and tPA
(within theclot), tetramericTTRmaybecleavedandthenrapidlydissociate intoamixtureof the truncatedresidue49–127 fragment (green) and full-lengthprotomers
(graysubunit). The releasedsubunitsmaygenerate the fibrillarnuclei (highlightedwithin the redcircle) that thenaggregate intoamyloid fibrils,whichaccumulate in the
extracellular space. The legend at the bottomof the figure identifies all the TTR species.
Plasmin primes TTR amyloidogenesis
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conditions was used to analyze protein composition before and
after fibril formation. After electrophoretic separation, samples
treated and untreated with trypsin or plasmin were blotted
onto an activated PVDF membrane. Western blotting was
developed with polyclonal sheep anti-human TTR (6 g/ml,
The Binding Site, United Kingdom/code AU066X) and poly-
clonal rabbit anti-sheep peroxidase conjugate (1.3 g/ml,
Dako, Denmark/code P0163) as primary and secondary anti-
bodies, respectively. Peroxidase activity was visualized using
a precipitating substrate containing 3,3-diaminobenzidine
and urea hydrogen peroxide (SigmaFAST DAB tablets,
Sigma-Aldrich).
Effect of2-antiplasmin on TTR fibril formation
Recombinant S52P TTR in 200 l volumes at 1 mg/ml in 20
mM Tris-HCl at pH 7.5, containing 150 mM NaCl, 5 mM CaCl2,
10 M ThT, was incubated at 37 °C in sealed Costar 24-well
black-wall plates, together with 20 ng/l of plasmin while sub-
jected to 900 rpm double-orbital shaking in the presence of
0.09, 0.18, 0.36, and 0.72 M 2-antiplasmin and in its absence.
Based on an average molecular mass of 55 kDa for plasmin, the
selected inhibitor concentrations corresponded to molar ratios
to plasmin of 0.25:1, 0.5:1, 1:1, and 2:1, respectively. ThT fluo-
rescence emission was monitored using a BMG LABTECH
FLUOstar Omega plate reader. Data were normalized to the
ThT signal plateau reached in the samples without the plasmin
inhibitor. All experiments were conducted in triplicate.
Fibrillogenesis of TTR variants andWT TTR
Recombinant S52P, V30M, L55P, V122I, WT and T119M
TTR in 500 l volumes at 1 mg/ml in 20 mM Tris-HCl contain-
ing 150 mM NaCl, 5 mM CaCl2, 10 M ThT, pH 7.5 were incu-
bated at 37 °C in sealed Costar 24-well black-wall plates,
together with 20 ng/l of plasmin while subjected to 900 rpm
double-orbital shaking. ThT fluorescence emission was moni-
tored until it reached a plateau. All experiments were con-
ducted in triplicate.
Preparation of amyloid seeds from S52P TTRwith plasmin
S52P TTR at 1 mg/ml in 20 mM Tris-HCl, 150 mM NaCl, 5
mM CaCl2, 10 M ThT, pH 7.5 was incubated at 37 °C with
plasmin at an enzyme:substrate ratio of 1:50 w/w in volume of
200 l in a 96-well black-wall plate. The plate was sealed with
clear sealing film, subjected to 900 rpm double-orbital shaking
and bottom fluorescence was recorded (BMG LABTECH
FLUOstar Omega). Aliquots of the final ThT positive material
were stained with alkaline alcoholic Congo Red and viewed
under high intensity cross-polarized light (26). Samples were
also examined by EM (Joel1200EX) after negative staining with
2% uranyl acetate (3). After further blotting and drying in air,
images were obtained at 80 kV.
Effect of seeds on plasmin-mediated S52P TTR fibrillogenesis
S52P TTR at 1 mg/ml in 20 mM Tris-HCl, 150 mM NaCl, 5
mM CaCl2, 10 M ThT, pH 7.5 was incubated at 37 °C with
plasmin at an enzyme:substrate ratio of 1:50 w/w in a volume of
200 l in a 96-well black-wall plate. S52P TTR fibrils, prepared
as described above, were added at the outset at 0.1 mg/ml to
three replicate wells; triplicate control well received addition of
buffer alone. The plate was sealed with clear sealing film, sub-
jected to 900 rpm double-orbital shaking, and bottom fluores-
cence was recorded at 500-s intervals (BMGLABTECHFLUO-
star Omega). Data were normalized to the highest value of ThT
signal after subtraction of the fluorescence intensity attributa-
ble to the added seeds alone.
Effect of plasmin on TTR amyloid fibrils
The concentration of S52P amyloid fibrils, produced as
described above, was measured by bicinchoninic acid protein
assay (Pierce). Fibrils at 0.1 mg/ml in 20 mM Tris-HCl, 150 mM
NaCl, 5 mM CaCl2, 10 M ThT, pH 7.5 in 200 l aliquots per
well were incubated at 37 °C in sealed Costar 96-well black-wall
plates in the presence or absence of plasmin at an enzyme:sub-
strate ratio of 1:50 w/w, with agitation as above. Bottom ThT
fluorescencewasmonitored at 500-s intervals as before in three
replicate test and control wells.
Fibrinolysis and/or fibril formation
The two-stage procedure comprised clot formation in phase
I followed by fibrinolysis and potential amyloid fibrillogenesis
in phase II. The experiments were conducted in Costar 96-well
black plates at 37 °C using a multimode plate reader (BMG
LABTECHFLUOstarOmega) tomonitor either changes in tur-
bidity at 350 nmorThT emission fluorescence. Fibrin polymer-
ization was initiated by adding thrombin (0.5 NIH units/ml) to
1 M human fibrinogen in 20 mM Tris-HCl, pH 7.5 containing
150 mM NaCl and 5 mM CaCl2 (buffer A) in a total volume of
100l per well. Clot formationwasmonitored by recording the
turbidity at 350 nm at 20-s intervals. After turbidity had
reached a stable level (usually within 30 min), 100 l of a solu-
tion containing tPA, plasminogen, and TTR in buffer A were
gently layered on top of the fibrin clot to a final concentration of
0.027 M, 1 M, and 18 M, respectively. The microtiter plate
was then sealed with clear sealing film, subjected to 900 rpm
double-orbital shaking and absorbance at 350 nm was mea-
sured at 500-s intervals at 37 °C. Blank subtraction and a cor-
rection based on the volume per well and the microplate
dimensions were used to normalize all absorption values to
1-cm path length. ThT at 10 M was present throughout. Bot-
tom fluorescence was recorded at 20-s intervals for 30 min in
stage I; after addition of tPA, plasminogen, and TTR in stage II,
the ThT signal wasmonitored at 500-s intervals for 20 h. Pellets
harvested at the end of stage II by centrifugation at 10,600 g
for 20 min were further analyzed by negative staining EM, light
microscopy after alkaline alcoholic Congo Red staining as
described above (26), and atomic force microscopy (AFM).
Atomic forcemicroscopy
Pellets harvested at the end of phase II were resuspended in
water and 100-fold diluted; 10l aliquots of the diluted samples
were deposited on freshly cleaved mica and dried under mild
vacuum. Samples in which no pellet was present were diluted
and deposited as described above, but after drying they were
rinsed with water to remove excess salts. Tapping mode AFM
images were acquired in air using a multimode scanning probe
microscope equipped with an “E” scanning head (maximum
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scan size, 10 m) and driven by a Nanoscope V controller
(Digital Instruments, Bruker). Single-beam uncoated silicon
cantilevers (type OMCL-AC160TS, Olympus and TESPA_
V2, Bruker) were used. The drive frequency was between 260
and 310 kHz; the scan rate was 0.25–0.5 Hz.
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